DDInter842 DDInter1763
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludarabine
Fludarabine {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} (Compound) binds {v} (Gene) NT5E
NT5E {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluorouracil
Fluorouracil {u} (Compound) binds {v} (Gene) PPAT
PPAT {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine and Fludarabine (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Temsirolimus (Compound)
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine (Compound) binds NT5E (Gene) and NT5E (Gene) is upregulated by Temsirolimus (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Temsirolimus (Compound)
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fluorouracil and Fluorouracil (Compound) binds PPAT (Gene) and PPAT (Gene) is downregulated by Temsirolimus (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Temsirolimus (Compound)